Vomiting of Pregnancy Clinical Trial
Official title:
Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy
Our purpose is to determine whether ondansetron, a commonly used antiemetic, is equivalent in efficacy to the combination of pyridoxine and doxylamine, the currently recommended first line therapy for nausea and vomiting in pregnancy by the American Congress of Obstetricians and Gynecologists (ACOG). Since both treatments are safe in pregnancy, many physicians are using ondansetron as first line in practice. Despite this practice and the recommendations from ACOG, there is not data to suggest that ether practice is superior. This will be the first prospective, randomized, double blind, controlled trial comparing the two treatments. We hypothesize that ondansetron will be equally efficacious in reducing nausea and episodes of emesis. By alleviating nausea and vomiting associated with pregnancy, patients will likely benefit from less Emergency Department visits, urgent clinic visits, and admissions for progression to hyperemesis gravidarum.
Status | Completed |
Enrollment | 36 |
Est. completion date | April 2013 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Women who are less than 16 weeks pregnant by last menstrual period or ultrasound - Greater than 18 years of age - English speaking - No significant visual or hearing impairment - Requesting treatment for nausea associated with pregnancy Exclusion Criteria: - If nausea or vomiting preexisted the pregnancy - Requires hospitalization at the time of initial enrollment - Already taking anti-emetics to include metoclopramide, ondansetron, doxylamine, pyridoxine, or promethazine - The patient has an allergy to either study regimen - If they are unable to return for a follow up visit in 1 week |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Naval Medical Center, San Diego | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
United States Naval Medical Center, San Diego |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduction of nausea on the VAS (Visual Analog Scale) | 5 days | No | |
Secondary | Reduction in vomiting on the VAS | 5 days | No | |
Secondary | Any adverse effects caused by the study medications. | 5 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06055192 -
Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
|
||
Not yet recruiting |
NCT04926727 -
Prevalence And Burden Of Nausea And Vomiting In Pregnant Women
|
||
Completed |
NCT05098067 -
Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
|
Phase 2 | |
Recruiting |
NCT05788796 -
The Effect of Band-Aid on Nausea-Vomiting During Pregnancy
|
N/A | |
Terminated |
NCT03785691 -
Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
|
Phase 2 | |
Completed |
NCT03320226 -
A Study of the Effect of Probiotics on Gastrointestinal Function During Pregnancy
|
N/A | |
Completed |
NCT06259747 -
Therapeutic Implications of Acutaping on Nausea and Vomiting During Pregnancy
|
N/A | |
Completed |
NCT05337852 -
Emotional Freedom Technique in Early Pregnancy
|
N/A |